On January 4th, Xiao Xiuying, director of Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, visited Shenzhen Cell Valley. Professor Shi Yuanyuan, Chairman of our company, Sun Rui, director of Marketing Department, Dr. Zhu Wenxiang, senior R&D scientist, and Wang Lu, director of general office warmly received and held a symposium.
Accompanied by Professor Shi Yuanyuan, Director Xiao visited the Shenzhen Cell Valley Wisdom Exhibition Hall and had a preliminary understanding of Shenzhen Cell Valley's strategic positioning, core technology, R&D team, product pipeline and clinical application cases. Then I went deep into the research and development, production and quality management laboratory, and had a more intuitive feeling of the actual operation process and quality management system.
At the symposium, Chairman Shi Yuan first shared the latest progress and clinical success cases of Shenzhen Cell Valley in the field of cell and gene therapy, demonstrating the innovation strength of Shenzhen Cell Valley in the field of medical health. He mentioned that Shenzhen Cell Valley has been committed to the development and application of cell therapy technology, and has achieved a number of important results. Subsequently, Director Xiao Xiuying introduced in detail the valuable experience of Renji Hospital in tumor treatment, especially the successful cases in precision medicine and immunotherapy, which provided an important reference for the scientific research and innovation of Shenzhen Cell Valley. At the same time, the two sides also held a heated discussion on the national policy orientation, and both sides agreed that the national policy orientation is an important guide for the development of the medical and health field, and only by following the national policy can we better grasp the development trend of the industry and promote the innovation and development of the medical and health field. Professor Shi Yuanyuan stressed that Shenzhen Cell Valley will actively respond to national policies, increase scientific research investment, promote the clinical application and industrialization of cell therapy technology, and provide more and better treatment programs for patients.

Director Xiao Xiuying recognized the core technology and clinical application cases mastered by Shenzhen Cell Valley. Director Xiao Xiuying, as the chief physician of the Department of Oncology, Doctor of Oncology, master's degree supervisor, and Administrative Director of the Department of Oncology, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, is good at the diagnosis and treatment of common diseases in the department of oncology, especially in the diagnosis and treatment of digestive tract tumors, lung cancer, neuroendocrine tumors has rich clinical experience. At the end of the symposium, the two sides reached a consensus on in-depth cooperation and promotion, indicating that they will carry out all-round cooperation in clinical research, technological innovation, personnel training and other aspects to jointly promote the development of the medical and health field.

This exchange not only enhanced the understanding and trust between the two sides, but also laid a solid foundation for future cooperation. The two sides jointly hope that Shanghai Renji Hospital and Shenzhen Cell Valley can jointly promote innovation and development in the field of healthcare, and bring benefits to more patients.